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Consecutive patient cultures (140) of Mycobacterium tuberculosis were collected from five Russian civilian
and prison tuberculosis laboratories and analyzed for rifampin (rpoB) and isoniazid resistance (inhA, katG,
ahpC); transmission of Beijing family isolates; and the importance of prison and previous therapy in drug
resistance. Rifampin, isoniazid, and multidrug resistance occurred in 58.2%, 51.6%, and 44.7% of cul-
tures, respectively; 80% of prison cultures were rifampin resistant. Spoligotyping and variable number tan-
dem repeat (VNTR) fingerprinting divided the isolates into 43 groups. Spoligotyping demonstrated that a
high proportion (68.1%) of patients were infected with Beijing family strains and that most (69.1%) were
rifampin resistant; the highest proportion (81.6%) occurred in prison. One VNTR subgroup (42435) com-
prised 68 (72.3%) of the Beijing isolates with a small number of IS6110 types; 50 (73.5%) were rifampin
resistant. Rifampin-resistant Beijing isolates are dominant within the patient population, especially among
prisoners, and threaten treatment programs.
he true extent of drug-resistant tuberculosis (TB) globally
is unknown. Few national surveys are representative and
validated by external laboratories (1,2). Accurate drug-suscep-
tibility testing is difficult to do well. The quality of results can
be further compromised if bacterial cultures originate from a
selected population from which key groups, such as prisoners,
have been omitted. Only limited susceptibility-testing data are
available in those countries with the highest rates of TB such
as India, Pakistan, Indonesia, China, and Russia. 
The spread of resistant isolates, especially multidrug-resis-
tant strains that are resistant to at least isoniazid and rifampin,
compromises both clinical efficacy and public health control
measures. Patients with infectious multidrug-resistant cases
continue to expectorate smear-positive sputum longer than
patients with drug-sensitive cases, increasing the probability of
spread of infection. The transmission of highly drug-resistant
strains has been documented within health-care institutions
and prisons (3–6), and the spread of one highly resistant strain,
W, has been documented from New York City to other U.S.
states and Puerto Rico (7). 
In Russia, TB incidence rates declined from the 1950s to
the 1990s; the lowest incidence and mortality rates were
recorded in 1991 (34.0/100 000 and 8.1/100 000, respec-
tively). By 1999, these rates had risen to 85.2/100 000 and
20.0/100 000, respectively (8–10). The average age of TB
patients has declined, reflecting high levels of recent transmis-
sion. Data on drug resistance for the whole of the Russian Fed-
eration are scarce; information comparable with international
data have been reported by the World Health Organization
from only 2 of the 89 oblasts (regions). In Ivanavo and Tomsk
Oblasts, the prevalence of multidrug-resistant TB was 9.0%
and 6.5%, respectively, in 1998–1999 (1,2). 
We initiated a pilot study in Samara, Russia, 1 of 89 oblasts
to determine the following: the value of genotypic methods for
identifying rifampin resistance and multidrug-resistant TB; the
extent of rifampin and multiple-drug resistance within the civil-
ian and prison systems; the extent to which this drug resistance
was associated with dominant strains, such as those of the
Beijing family, by using molecular DNA fingerprinting tech-
niques; and whether drug resistance was associated with being
a prisoner or with previous TB treatment. 
DNA fingerprinting that uses techniques such as restriction
fragment length polymorphism (RFLP) based on IS6110 is the
international standard for documenting transmission at the
molecular level (11–14). Rapid techniques that use polymerase
chain reaction (PCR) amplification such as spacer-oligonucle-
otide typing (spoligotyping) (13–15) are usually less discriminat-
ing but may provide greater information on evolutionary origins
and can be used when cultures are contaminated or nonviable. 
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Spoligotyping is particularly valuable in defining strains
belonging to the Beijing family as well as subspeciating strains
of the Mycobacterium tuberculosis complex and does not
require viable organisms. The Beijing family of isolates was
first reported at a high rate in the Beijing area in 1995 (16) and
less frequently in other parts of Asia such as Vietnam (17).
These isolates may be associated with a higher occurrence of
drug resistance; for instance, the highly drug-resistant W
strain, first identified in New York, is a member of the Beijing
family (7,18). These isolates have previously been frequently
seen in convenience samples taken in the Russian Federation
(18,19). In our study, isolates were collected from both the
prison and civilian sectors at the same time in one region of the
Russian Federation. These isolates were analyzed with molec-
ular epidemiologic techniques (spoligotyping, variable number
tandem repeat [VNTR], rapid epidemiological typing
[RAPET], IS6110) to characterize the role of Beijing isolates
and molecular genotypic methods to determine rifampin, iso-
niazid, and multidrug resistance.
Methods
Population
All cultures of M. tuberculosis growing from February 1 to
March 31, 2001, and May 14 to August 30, 2001, from five
principal civilian and prison laboratories were analyzed: the
Oblast Regional TB Laboratory (oblast laboratory), the
Samara City Dispensary Laboratory no 1 (city dispensary),
Samara City Hospital no. 1 (city hospital), Novokuibyshevsk
Novokuibyshevsk Town Laboratory (Novokuibyshevsk labo-
ratory), and Prison Colony no. 19 (prison colony). A single
culture from each patient was analyzed. These five laborato-
ries cover 40% of the population of this region with TB and
are representative of the TB caseload in Samara Oblast. The
oblast laboratory acts as the oblast reference/referral center; it
has direct responsibility for rural areas, data collection for the
oblast, and methodologic and organizational issues. The city
dispensary receives cultures for drug-susceptibility testing
from all five laboratories covering the outpatient caseload
from the capital, Samara City; city hospital is the main inpa-
tient facility. Novokuibyshevsk laboratory is the central TB
laboratory; it serves a medium-sized industrial town. All
patients with TB in the prison sector receive their inpatient
treatment within the prison colony; the prison laboratory ana-
lyzes all positive cultures from prisoners. Gender, date of birth
or age, date of culture, phenotypic drug-susceptibility results,
prison status, and history of previous treatment were deter-
mined by direct questioning of each person and examining the
medical and laboratory notes. The study was approved and
supervised by the local drug-susceptibility testing and ethics
steering committee.
Drug Resistance
All sputum specimens were cultured on Lowenstein-
Jensen media; specimens were coded so that those performing
the laboratory analysis were unaware of the epidemiologic
data. Rifampin, isoniazid, and multidrug resistance were deter-
mined genotypically. DNA was chloroform-extracted (20),
and rifampin resistance was determined by using a nested
PCR-amplification approach. The PCR product was reverse
hybridized to probes immobilized on a membrane to detect
mutations within the rpoB gene (21–23) (INNO-LiPA Rif.Tb;
Innogenetics, Ghent, Belgium).
With the use of biotinylated primers, an inhouse macroar-
ray was developed and used to identify mutations associated
with isoniazid resistance in the genes inhA, katG, and ahpC
(24). Briefly, crude bacterial lysates were prepared from each
isolate as described above (20). With the use of published M.
tuberculosis sequences, digoxigenin-labeled PCR products
were generated in a multiplex PCR amplifying four genomic
sequences associated with resistance to isoniazid: 251- and
232-bp regions of katG, including codon 315 and codon 463, a
241-bp region of aphC-oxyR; and a 265-bp region of the inhA
locus, including the regulatory region. The sequences used to
design the PCR primers were MTU06270 for katG, MTU16243
for aphC, and MTU66801 for inhA. Primer sequences were:
tomkp 1 = GGCCCCGAACCCGAGGCTGC; tomkp2 =
AACGGGTCCGGGATGGTGCCG; tomkp3 = GCCGACGAG
TTCGCCAAGGCC; tomkp4 = ACGACGCCGCCGCCCAT-
GCG; tomap1 = CCGCCGATGAGAGCGGTGAGC; tomap2
= CCACTGCTTTGCCGCCACCGC; tomip1 = CACCCG-
CAGCCAGGGCCTCG; and tomip2 = CGATCCCCCGGTTT
CCTCCGG.
PCR was conducted in a 25-µL reaction containing 2.5 µL
10X reaction buffer (Qiagen, Crawley, UK), 0.5 µL 2 mM
dNTP (deoxynucleoside triphosphate; Pharmacia, Little Chal-
font, UK), 20 µM each of the eight primers, 0.05 nmol dUTP
(digoxigenin-labeled deoxyuridine triphosphate; Roche,
Lewes, UK), 0.5 U of HotStartaq (Qiagen), and 1 µL DNA
extract. Cycling was conducted with a PE2400 thermal cycler
(Applied Biosystems, Foster City, CA) programmed to hold
95°C for 15 min then 30 cycles of 15 sec at 95°C, 30 sec at
60°C, and 60 sec at 72°C.
Eleven probes for the macroarray were diluted in water to
20 µM and applied to printed cells on a numbered nylon mem-
brane (Osmonics, Minnetonka, MN). The oligonucleotides
were UV-crosslinked for 1 min in an Amplirad UV box (GRI,
Braintree, UK). Membranes were washed twice for 5 min in
0.5XSSC (1X SSC is 0.15 M NaCl plus 0.015 M sodium cit-
rate) and air-dried. The individual arrays were then separated
and placed in a 2.5-mL minifuge tube. These were stored in
darkness at room temperature until use. A reverse hybridiza-
tion procedure was used to interrogate the macroarray, and
hybridization was visualized by detecting the digoxigenin
label colorimetrically according to the manufacturer’s instruc-
tions (Roche). Extensive precautions (including the use of a
three-room PCR suite, dedicated equipment, and multiple pos-
itive and negative controls) were taken to avoid cross-contam-
ination.
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All cultures were analyzed by spoligotyping (15) and
VNTR analysis (25) by using standard methods. For VNTR
analysis, PCR-amplification was performed to identify the
number of exact tandem repeats at five loci, A to E. PCR prod-
ucts were electrophoresed on a sieving agarose gel to deter-
mine the size of the product and compared against a standard
to determine the number of exact tandem repeats at each locus.
The result can be read as a numerical code that can be com-
pared across large groups of isolates. RAPET was performed
as described by Yates et al. (2). Fifty-five viable cultures were
available for RFLP typing, targeting the IS6110 by using the
internationally standardized protocol described by van Emb-
den et al. (11).
Results
Drug Resistance
One hundred forty cultures were collected from the five
sites, and genotypic analysis was performed in London by
British and Russian scientists to determine rifampin and iso-
niazid resistance (Table 1). One hundred thirty-four cultures
were successfully amplified (four cultures gave no amplifica-
tion, and two cultures were identified as M. gordonae). Over-
all, 78 (58.2%) had mutations consistent with rifampin
resistance. The Innolipa assay may underestimate true
rifampin resistance by 5% to 7% (21,23). Detection of muta-
tions, however, is indicative of true rifampin resistance in
nearly all cases. Table 1 indicates the overall rate of rifampin
resistance, the rate for each laboratory center, and the rate of
molecular rifampin resistance as a fraction of each laboratory
culture population.
A macroarray was used to identify isoniazid resistance in
128 cultures that could be evaluated (amplification products
were absent in 6 cultures successfully amplified for rpoB).
When this method was used, 66 (51.6%) isolates were iso-
niazid resistant, and 62 were sensitive. This technique only
detects approximately 75% to 90% true resistance so the rate
of resistance is underestimated. Table 1 indicates the propor-
tions of isoniazid-resistant cultures from each center; most
came from the prison TB laboratory. Patient age and being a
prisoner were significant risk factors for rifampin but not iso-
niazid resistance; previous treatment was a risk factor for
resistance to both drugs (Table 2). 
Beijing Family and Molecular Epidemiology
Of the 140 original samples, 138 produced a spoligotype
profile. The samples were divided into 27 groups with 16 indi-
vidual isolates and 10 clustered groups: 5 clusters containing 2
isolates, 2 with 3 isolates, 1 with 4 isolates, and 1 with 8 iso-
lates. The 10th cluster accounted for 94 (68.1%) of the 138
cultures and comprised the characteristic Beijing strain (i.e.,
binding occurred only to the final nine spoligotype probes).
When VNTR typing was used, 136 isolates (4 did not amplify)
were divided into 25 groups: 13 were individual profiles with
4 clusters containing 2 isolates, 2 clusters of 3 isolates, 1 clus-
ter of 4 isolates, 2 clusters of 5 isolates, 1 cluster of 9 isolates,
1 cluster of 13 isolates, and a dominant cluster of 73 strains.
Combining spoligotyping and VNTR typing divided the 138
strains into 44 types in total.
The proportion of Beijing isolates compared to the total
number of cultures submitted by each site was calculated
(Table 3). Both the total number and highest proportion of
Beijing family cultures came from the prison and the oblast
TB dispensary, which would be inclined to have complicated
cases, including ones in former prisoners.
Beijing Strains and Drug Resistance
Overall, 65 (69.1%) of 94 Beijing family cultures were
rifampin resistant (Table 4); the highest proportion of
rifampin-resistant Beijing isolates (31/38 or 81.6%) occurred
in the prison. Proportions at the other centers varied from
60.0% to 77.8%.
High rates of rifampin resistance were seen in Beijing iso-
lates from all centers. Overall, the proportion of Beijing iso-
lates with rifampin resistance was over twice that of non-
Beijing isolates (69.1% vs. 29.5%). The Beijing cluster of 94
isolates was subtyped by using VNTR (Table 5); 92 isolates
were successfully analyzed, and no amplification occurred in 2
isolates. Overall, the 91 Beijing isolates were subdivided into
Table 1. Molecular resistance to rifampin and isoniazid in Mycobacterium tuberculosis isolates with proportional analysis by center/laboratory, 
Samara Oblast, Russian Federation
Laboratory location
No. of isolates examined for 
rifampin resistance (n=130)a
No. of rifampin-resistant 
isolates (%)
No. of isoniazid-resistant 
isolates (%)b
All 134 78 (58.2) 66 (–)
Prison TB colony   45 36 (80.0) 27 (60.0)
City dispensary 1   11   4 (36.4)   4 (36.4)
City hospital 1   34 18 (52.9) 14 (41.2)
Novokuibyshevsk town labora-
tory 
  21   9 (42.9)  11 (52.4)
Oblast regional TB laboratory   19 11 (57.9)  10 (52.6)
aOf 140 cultures, 134 results were produced, but only 130 were available for results by center; 2 were M. gordonae, amplification failed for 4 cultures, and center could not be defini-
tively identified for 4. 
bOf 140 cultures, amplification products that could be evaluated were obtained from 128 cultures.
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13 groups with 8 individual VNTR types and 2 different clus-
ters of 2 isolates, 1 cluster each of 3 isolates and 1 of 9 isolates.
The 13th cluster contained 68 isolates (VNTR 42435) or
72.3% of the total number of Beijing isolates seen. Most iso-
lates within this VNTR type were rifampin resistant: 50
(73.5%) of 68 were resistant, 16 (23.5%) were sensitive, and 2
had equivocal results. Within this dominant VNTR type, the
proportion of the type that was rifampin resistant by institution
was calculated (Table 6). Within the prison and oblast dispen-
sary 90% to 91% of the strains of the VNTR 42435 type were
rifampin resistant.
Of the 55 viable isolates that were RFLP-IS6110 finger-
printed, 23 were members of the main VNTR 42435 group
(Figure). A small number of similar but distinct isolates were
seen across the sites, including the W148 strain seen in Sibe-
rian prisons and elsewhere in the former Soviet Union (18).
This observation was confirmed by RAPET typing (data not
shown).
Discussion
This analysis is part of an ongoing program to develop the
capacity to accurately determine drug resistance and monitor
the epidemiology of drug-resistant TB in both civilian and
prison sectors in Russia. For multidrug-resistant TB, cure rates
are lowered and infectious patients remain sputum smear-posi-
tive longer, increasing the probability that others will be
infected.
As part of this program, we initiated a collaborative study
in Samara, Russia, 1 of 89 regions or oblasts within the Rus-
sian Federation. In 2000, the new case rate in Samara was
87.6/100,000 (2,890 cases) in a population of 3,308,000
(including nonresidents and prisoners) with a death rate of
13.6 /100,000 (443 cases) (9,10). TB appears to be a problem
in all Russian prisons including those in Samara, where the
total number of TB patients at the time of the study was 1,800
cases (~34% of all registered TB patients in the region) (9,10).
Because of an increasing number of intravenous drug users in
the region, the problem of coinfection with HIV is likely to
become increasingly important as the number of HIV-positive
persons increases (>12,000 HIV-infected persons were regis-
tered in Samara Region in May 2001). 
When molecular genotypic resistance analysis was used,
58.2% of cultures were rifampin resistant, and at least 51.6%
were shown to be isoniazid resistant. Within this population,
there were 123 molecular results for both rifampin and iso-
niazid, and 55 cases were definitely multidrug-resistant TB
(55/123 or 44.7%); and 24 were possible cases (i.e., resistant
to rifampin but sensitive to isoniazid with genotypic methods).
These rates are high for both rifampin resistance and multi-
drug-resistant TB. Nevertheless, care must be taken in inter-
preting these results: they are likely to be overestimates since
cultures were derived from new and chronic cases. Very high
rates of rifampin resistance were seen in cultures drawn from
the prison TB colony (80%), and 35 (79.5%) of 44 patients
with known rifampin-resistant cases had been in prison before.
Being a prisoner and patient age were risk factors for rifampin
Table 2. Patient factors associated with rifampin- and isoniazid-resis-
tant isolatesa
Factor
Rifampin resistance 
(n=78)
Isoniazid resistance 
(n=66)
Age p<0.05b p>0.05
Known prisoner RR 1.68,b CI 1.29 
to 2.18
RR 1.36, CI 0.97 
to 1.89
Known previous 
treatment 
RR 1.71,b CI 1.07 
to 2.74
RR=2.04,b CI 1.01
 to 4.10
aRR, risk ratio; CI, confidence interval.
bStatistically significant
Table 4. Number and proportion of rifampin resistant isolates within Beijing family at each center
Location No. of Beijing isolates
No. of Beijing isolates 
resistant to rifampin (%)
No. of isolates 
resistant to rifampin
% of rifampin-resistant isolates 
that belong to Beijing family
All 94 65 (69.1) 78 83.3
Prison TB colony 40 31 (77.5) 36a 86.1
City hospital 1 18 14 (77.8) 18 77.8
Novokuibyshevsk town laboratory 12   7 (58.3)   9 77.8
Oblast regional TB laboratory 14 10 (71.4) 11 90.9
aFour gave no amplification; numbers too small to evaluate for city dispensary l.
Table 3. Proportion of Beijing family in isolates of Mycobacterium 
tuberculosis with distribution by center/laboratory, Samara Oblast, 
Russian Federation
Location
No. of isolates available
 for typing (n= 138)a
No. of Beijing family 
isolates (%)
All 138 94b (68.1)
Prison TB colony   49  40 (81.6)
City dispensary 1   11    6 (54.5)
City hospital 1   34  18 (52.9)
Novokuibyshevsk town 
laboratory 
   21 12 (57.1)
Oblast regional TB 
laboratory
  19 14 (73.7)
aOf 140 cultures, 138 were available for spoligotyping (2 were not multiresistant TB); 
however, 4 cultures could not be attributed to a center.
b138 cultures were evaluated, but 4 could not be attributed to a specific center, i.e., 134 
attributable cultures.
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resistance (but not for isoniazid resistance). Previous treatment
was a risk factor for both rifampin and isoniazid resistance. 
It remains unclear whether rifampin resistance is being
introduced into the oblast prison from the pretrial centers or
developing within prison because of interrupted therapy
caused by poor adherence to treatment or release before treat-
ment is completed. Previous treatment has been shown to be a
risk factor for drug resistance (1,2). 
Molecular epidemiologic techniques can help monitor the
spread of TB isolates. These techniques will be of particular
value where drug resistance is common and where strains such
as the Beijing family appear more commonly associated with
the type of drug resistance likely to lead to therapeutic failure
and prolonged infectivity. In this study, rapid PCR-based tech-
niques such as spoligotyping were used; although less discrim-
inating than IS6110-RFLP analysis, PCR techniques permitted
safe, rapid analysis of a specific family of strains. Spoligotyp-
ing’s ability to discriminate was greater than that of VNTR; in
combination, the techniques divided the isolates into 43
groups, indicating the benefits of combining these systems.
Spoligotyping demonstrated a high proportion (94 [68.1%] of
the 138 cultures) of the characteristic Beijing family of strains,
which has been previously associated with drug resistance. 
Some researchers have argued that the Beijing genotypes
may have a selective advantage over other genotypes; BCG-
induced immunologic protection may not protect against this
strain, which would be an “escape mutant” (17). In that study
in Vietnam, although the Beijing isolates were occurring more
frequently among those vaccinated with BCG, this difference
was not statistically significant (17). In that study, more
Beijing isolates occurred in younger age groups, suggesting
possible recent transmission; in our analysis, patients with
Beijing isolates were younger than those with non-Beijing iso-
lates (data not shown), which might support this conjecture.
Other researchers have argued against any selective advantage,
pointing out that Beijing isolates have spread widely in the
United States, where BCG vaccination is not used (18). Never-
theless, BCG vaccination may accelerate the dominance of this
family in regions once the strains have been introduced. The
Russian Federation TB Service has a comprehensive program
of BCG vaccination, which might create a selection pressure.
Analysis using VNTR also demonstrated a dominant VNTR
type containing 68 (72.3%) isolates (VNTR 42435) of the total
number of Beijing isolates. A small number of similar but dis-
tinct isolates were seen on RFLP-IS6110 fingerprinting,
including the W148 strain (17 band) seen in Siberian prisoners
and elsewhere in the former Soviet Union (18). In 1998–2000,
this strain was seen in 190 prisoners with multidrug-resistant
TB in a prison in Tomsk, Western Siberia (18,19). None of the
Samaran prisoners were from Siberia.
Another probable reason for the successful expansion of
the Beijing family is its association with multidrug-resistant
TB; Beijing types such as W4 and “210” appear widespread in
China but are fully susceptible to drugs (18). Low cure rates of
smear-positive prisoners would lead to prolonged infectivity.
The oblast prison, in particular, has a high proportion of
Beijing isolates and a high rate of rifampin resistance, suggest-
ing that the Beijing family is dominant there and accounts for a
large proportion of resistance. Nevertheless, drug resistance
per se cannot be the only explanation for the success with
these isolates.
The widespread population movements during the first
half of the 20th century may have helped to distribute these
isolates into new communities, which were then subsequently
Table 5. Variable number tandem repeat (VNTR) analysis of Beijing 
isolates (n=91) and comparison with rifampin sensitivity
VNTR
Total in each 
VNTR type
No. of rifampin 
resistant in each type
No. of rifampin 
sensitive in each type
12435 3 3 0
12534 9 8 1
12535 1 1 0
22232 2 0 2
22435 1 0 1
32413 1 - –a
32433 1 0 1
32435 1 0 1
42234 1 0 1
42434 2 0 2
42435 68 50 16 (2 mixed=nonreadable)a
42436 1 1 0
42532 1 1 0
a In three, no amplification of rpoB gene or mixed reaction.
Table 6. Proportion of dominant variable number of tandem repeat (VNTR) isolates of type 42435 known to be resistant or sensitive, by institution
Location Proportion (n=68) No. of VNTR type resistant to rifampin  (%)a Proportion of VNTR type sensitive to rifampin (%)
Prison TB colony 30 27 (90) 3 (10)
City dispensary 5   3 (60) 2 (40)
City hospital 1 7      3 (42.9)    4 (57.1)
Novokuibyshevsk town laboratory 12      7 (58.3)    5 (41.7)
Oblast regional TB laboratory 11    10 (90.9) 1 (9.1)
aNo rpoB amplification in one culture in this group.
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selected for by the introduction of a comprehensive BCG vac-
cination policy and by the later development of drug resis-
tance. Concluding that Beijing family isolates have un-
discovered advantages is also reasonable. In this study a large
proportion of the Beijing isolates were of the same VNTR type
(42435), but little is known of any differences in biologic func-
tion that might be related to different types. A recent study has
demonstrated that the coding sequence Rv3710 (leuA)
encodes the production of active alpha-isopropylmalate syn-
thase. Within the sequence lies the locus of VNTR 4155, and
this may have a modifying role on the function of the enzyme
(26). 
High-quality national or regional drug resistance surveys
are needed in other parts of the Russian Federation. Such sur-
veys would lead to a clearer understanding of the true level of
drug resistance and in turn facilitate clinical management and
permit better empirical treatment strategies. Genotypic tech-
niques are of value in determining rifampin resistance and
likely multidrug-resistant TB. Although expensive compared
to drug-susceptibility testing on solid media, genotyping tech-
niques may be justified in populations with high levels of mul-
tidrug-resistant TB and high rates of concurrent HIV. Further
analysis is required to confirm the spread of the Beijing family
and determine whether it is imported into the prison and
spread within the prison community. 
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